The drug is an under-the-skin injection that women would use about 45 minutes before anticipated sexual activity. It is intended to increase desire in women who experience “low sexual desire that causes marked distress or interpersonal difficulty.”
The approval of Vyleesi is controversial, according to STAT. Critics claim that prescribing a drug to increase sexual desire reduces the complexity of human sexuality to a biological issue.
More articles on pharmacy:
Lupin recalls 18,408 bottles of antibiotic in US
Bluebird Bio prices gene therapy at $1.8M
10 hospitals seeking pharmacy leaders
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
